TAMPERE, Finland, Feb. 14, 2025 /PRNewswire/ — Bioretec Ltd., a pioneer in absorbable orthopedic implants, has achieved a pivotal milestone with the successful completion of its CE mark approval process for the RemeOs™ Trauma Screw product portfolio

A Medtronic (NYSE: MDT)+
official said today on LinkedIn that the company won CE mark for its Crescent RA jugular dual lumen catheter.

Accelus this week announced its FlareHawk Interbody Fusion System received regulatory approval in Brazil.

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.

A team of researchers has developed a “gut-on-chip” (a miniature model of the human intestine on a chip-sized device) capable of reproducing the main features of intestinal inflammation and of predicting the response of melanoma patients to immunotherapy treatment. The results have just been published in Nature Biomedical Engineering.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted treatments known as CDK4/6 inhibitors. A new study led by Agnieszka Witkiewicz, MD, and Erik Knudsen, Ph.D., of Roswell Park Comprehensive Cancer Center and colleagues highlights the therapeutic impact of CDK2 inhibitors and is published in the journal Nature Communications.

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily eye drops to treat glaucoma, a leading cause of blindness.

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to trigger cell therapies for various metabolic diseases.